Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Kumada H
Department of Gastroenterology, Toranomon Hospital, Minato-Ku, Tokyo, Japan.
Hepatology. 1997 Mar;25(3):745-9. doi: 10.1002/hep.510250342.
Hepatitis C virus (HCV) genotype 1b and high pretreatment virus load are predictive factors of poor response to interferon therapy in patients with chronic hepatitis C. To further examine the factors predicting the response to interferon in patients with genotype 1b infection, we analyzed 110 consecutive patients with HCV who were treated with a total of 624 million units of lymphoblastoid interferon alfa. Thirty-six patients (33%) were responders, while the remaining 74 patients (67%) were nonresponders. Multivariate analysis showed that a high virus titer (assessed by serum core protein level, P = .0021) and the presence of more than two amino acid substitutions in the interferon sensitivity-determining region (ISDR) (P = .0036) correlated significantly with the response to interferon therapy. Because mutations analyzed by direct sequencing of polymerase chain reaction (PCR) products may reflect artifacts of direct sequencing, we further analyzed quasispecies of HCV in this region by cloning and sequencing. Although PCR-based analysis of responders with multiple amino acid substitutions in the ISDR showed the presence of a small amount of wild-type strain in their serum, the results obtained by direct sequencing and cloning were essentially the same. A longitudinal study of quasispecies in 2 patients who showed a dramatic change in the virus titer showed no conversion from wild type to mutant or vice versa. Our results indicate that amino acid substitutions and virus load are independent predictors of the response to interferon therapy. The ability of some patients with no mutation in the ISDR or high virus load to eliminate the virus suggests the presence of other unidentified factors, host or viral, that influence the response to interferon therapy.
丙型肝炎病毒(HCV)1b型和治疗前高病毒载量是慢性丙型肝炎患者对干扰素治疗反应不佳的预测因素。为了进一步研究预测1b型感染患者对干扰素反应的因素,我们分析了110例连续接受总计6.24亿单位淋巴母细胞干扰素α治疗的HCV患者。36例患者(33%)有反应,其余74例患者(67%)无反应。多变量分析显示,高病毒滴度(通过血清核心蛋白水平评估,P = 0.0021)和干扰素敏感性决定区(ISDR)中存在两个以上氨基酸替代(P = 0.0036)与干扰素治疗反应显著相关。由于通过聚合酶链反应(PCR)产物直接测序分析的突变可能反映直接测序的假象,我们通过克隆和测序进一步分析了该区域HCV的准种。尽管基于PCR分析的ISDR中有多个氨基酸替代的有反应者血清中存在少量野生型毒株,但直接测序和克隆获得的结果基本相同。对2例病毒滴度有显著变化的患者进行的准种纵向研究显示,未出现从野生型到突变型或反之的转变。我们的结果表明,氨基酸替代和病毒载量是干扰素治疗反应的独立预测因素。一些ISDR无突变或病毒载量高的患者能够清除病毒,这表明存在其他未明确的宿主或病毒因素影响对干扰素治疗的反应。